ECFS 2020 - Optimizing pharmaceutical care in cystic fibrosis

European Cystic Fibrosis Society   229  OPTIMIZING PHARMACEUTICAL CARE IN CYSTIC FIBROSIS OPTIMIZING PHARMACEUTICAL TREATMENT IN CYSTIC FIBROSIS CHAPTER 12 [24] Corcoran A, Hickey N, Barry M, Usher C, McCullagh LM. Ivacaftor for cystic fibrosis: An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting. Ir Med J. 2017;110(7):619-. [25] Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infectious Agents and Cancer. 2016;11(1). [26] Trusheim MR, Cassidy WM, Bach PB. Alternative State-Level Financing for Hepatitis C Treatment—The “Netflix Model”. JAMA. 2018;320(19):1977. [27] Moon S, Erickson E. Universal Medicine Access through Lump-Sum Remuneration — Australia’s Approach to Hepatitis C. N Engl J Med. 2019;380(7):607-10. [28] Trusheim M, Bach PB. Health Affairs [Internet]. Affairs H, editor. Health Affairs: Health Affairs. 2019. [cited 2020]. Available from: https:// www.healthaffairs.org/do/10.1377/ hblog20190924.559225/full/ . [29] Culliton G. Risk-sharing scheme mooted for CF drug Irish Medical Times 2013 [Available from: https://www.imt.ie/news/risk- sharing-scheme-mooted-for-cf- drug-25-01-2013/ . [30] Yu JS, Chin L, Oh J, Farias J. Perfor- mance-Based Risk-Sharing Arrange- ments for Pharmaceutical Products in the United States: A Systematic Review. JJ Manag Care Spec Pharm. 2017;23(10):1028-40. [16] Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technology Assessment. 2015;19(14):1-504. [17] Paulden M. Recent amendments to NICE’s value-based assessment of health technologies: implicitly ineq- uitable? Expert Review of Pharma- coeconomics & Outcomes Research. 2017;17(3):239-42. [18] Largent EA, Pearson SD. Which Orphans Will Find a Home? The Rule of Rescue in Resource Allocation for Rare Diseases. Hastings Center Report. 2012;42(1):27-34. [19] NICE. Citizens Council Report: Rule of Rescue 2006. [20] Schuhmacher A, Gassmann O, Hinder M. Changing R&D models in research- based pharmaceutical companies. J Transl Med. 2016;14(1). [21] Reuters. 2014 CMR International Phar- maceutical R&D Factbook. 2014. [22] Balfour-Lynn IM. Personalised medi- cine in cystic fibrosis is unaffordable. Paediatr Respir Rev. 2014;15:2-5. [23] Freeman G. George Freeman (MP) responds to parliamentary debate on accessing drugs for ultra-rare diseases. https://www. georgefreeman.co.uk/content/ george-freeman-responds-parliamen- tary-debate-accessing-drugs-ultra-ra- re-diseases2015 .